Immunic (NASDAQ:IMUX – Get Rating) had its price objective lowered by equities research analysts at Aegis from $40.00 to $35.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.
A number of other research firms also recently commented on IMUX. Wedbush dropped their price objective on Immunic from $61.00 to $14.00 in a report on Thursday, June 2nd. SVB Leerink decreased their price objective on shares of Immunic from $45.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, June 3rd. Finally, Piper Sandler cut their target price on shares of Immunic from $71.00 to $39.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.40.
Immunic Price Performance
IMUX traded down $0.50 during trading on Monday, hitting $4.83. The company’s stock had a trading volume of 7,714 shares, compared to its average volume of 476,503. The firm’s 50 day moving average price is $3.89 and its 200-day moving average price is $7.88. The stock has a market cap of $147.51 million, a PE ratio of -1.59 and a beta of 2.10. Immunic has a twelve month low of $2.52 and a twelve month high of $14.50.
Immunic (NASDAQ:IMUX – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.06. Equities analysts anticipate that Immunic will post -2.86 earnings per share for the current year.
Insider Activity
In related news, Chairman Duane Nash acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was acquired at an average cost of $5.03 per share, for a total transaction of $50,300.00. Following the completion of the acquisition, the chairman now directly owns 22,032 shares of the company’s stock, valued at approximately $110,820.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders purchased 28,500 shares of company stock worth $127,380 over the last three months. Corporate insiders own 5.00% of the company’s stock.
Institutional Trading of Immunic
A number of large investors have recently added to or reduced their stakes in IMUX. Otter Creek Advisors LLC boosted its holdings in Immunic by 20.0% during the fourth quarter. Otter Creek Advisors LLC now owns 120,000 shares of the company’s stock worth $1,148,000 after buying an additional 20,000 shares in the last quarter. KCK LTD. acquired a new position in Immunic in the 4th quarter worth approximately $667,000. Soleus Capital Management L.P. acquired a new position in Immunic in the 4th quarter worth approximately $1,675,000. Point72 Asset Management L.P. boosted its stake in Immunic by 16.0% in the 4th quarter. Point72 Asset Management L.P. now owns 725,000 shares of the company’s stock worth $6,938,000 after purchasing an additional 100,000 shares during the period. Finally, Altium Capital Management LP boosted its stake in Immunic by 890.0% in the 4th quarter. Altium Capital Management LP now owns 317,000 shares of the company’s stock worth $3,034,000 after purchasing an additional 284,979 shares during the period. 49.03% of the stock is currently owned by institutional investors.
About Immunic
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.